Regeneron Pharmaceuticals, Inc. (BMV:REGN)

Market Cap	1.23T
Revenue (ttm)	287.90B
Net Income (ttm)	91.96B
Shares Out	n/a
EPS (ttm)	805.86
PE Ratio	13.36
Forward PE	15.50
Dividend	17.99 (0.15%)
Ex-Dividend Date	May 20, 2025

Volume	n/a
Average Volume	81
Open	11,620
Previous Close	11,620
Day's Range	11,620 - 11,620
52-Week Range	11,435 - 23,707
Beta	n/a
RSI	31.04
Earnings Date	May 2, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD